- Home
- DCI vs INTS Comparison
DCI vs INTS Comparison
Compare DCI & INTS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DCI
- INTS
- Stock Information
- Founded
- DCI 1915
- INTS 2012
- Country
- DCI United States
- INTS United States
- Employees
- DCI N/A
- INTS N/A
- Industry
- DCI Pollution Control Equipment
- INTS Biotechnology: Pharmaceutical Preparations
- Sector
- DCI Industrials
- INTS Health Care
- Exchange
- DCI Nasdaq
- INTS Nasdaq
- Market Cap
- DCI 7.9B
- INTS 30.8M
- IPO Year
- DCI 1987
- INTS 2023
- Fundamental
- Price
- DCI $67.63
- INTS $0.57
- Analyst Decision
- DCI Hold
- INTS Strong Buy
- Analyst Count
- DCI 4
- INTS 3
- Target Price
- DCI $71.33
- INTS $8.50
- AVG Volume (30 Days)
- DCI 528.3K
- INTS 354.7K
- Earning Date
- DCI 06-03-2025
- INTS 05-20-2025
- Dividend Yield
- DCI 1.59%
- INTS N/A
- EPS Growth
- DCI 11.79
- INTS N/A
- EPS
- DCI 3.42
- INTS N/A
- Revenue
- DCI $3,633,400,000.00
- INTS N/A
- Revenue This Year
- DCI $3.00
- INTS N/A
- Revenue Next Year
- DCI $3.49
- INTS N/A
- P/E Ratio
- DCI $19.34
- INTS N/A
- Revenue Growth
- DCI 4.46
- INTS N/A
- 52 Week Low
- DCI $57.45
- INTS $0.50
- 52 Week High
- DCI $78.95
- INTS $5.28
- Technical
- Relative Strength Index (RSI)
- DCI 59.45
- INTS 18.34
- Support Level
- DCI $65.72
- INTS $0.54
- Resistance Level
- DCI $67.61
- INTS $0.59
- Average True Range (ATR)
- DCI 1.28
- INTS 0.13
- MACD
- DCI 0.45
- INTS -0.04
- Stochastic Oscillator
- DCI 92.95
- INTS 4.72
About DCI Donaldson Company Inc.
Donaldson is a leading manufacturer of filtration systems and replacement parts (including air filtration systems, liquid filtration systems, and dust, fume, and mist collectors). The company serves a diverse range of end markets, including construction, mining, agriculture, truck, and industrial. Its business is organized into three segments: mobile solutions, industrial solutions, and life sciences. Donaldson generated approximately $3.6 billion in revenue and $544 million in operating income in its fiscal 2024.
About INTS Intensity Therapeutics Inc. Common stock
Intensity Therapeutics Inc is a clinical-stage biotechnology company pioneering a new immune-based approach to treat solid tumor cancers. The company leverages its DfuseRxtechnology platform to create new, proprietary drug formulations that, following direct injection, rapidly disperse throughout a tumor and diffuse therapeutic agents into cancer cells. Intensity's product candidates have the potential to induce an adaptive systemic immune response that not only attacks the injected tumor, but also non-injected tumors. Their pipeline is focused on realizing the full potential of INT230-6 in metastatic and local disease settings to help cancer patients with unmet medical need.